Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by ... syndromes. This study is based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621). ...

    Research Article last updated 04/23/2014 - 12:26pm.

  2. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... changing MDS environment is raising new challenges in clinical trial design and defining new indications for MDS drugs. Many current ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... is expanding rapidly, but limited comparative clinical trial data are available to (i) define the optimal use of azacitidine in ...

    Research Article last updated 07/09/2013 - 3:03pm.

  4. Pharmacotherapy of myelodysplastic syndromes.

    ... molecular pathways that account for disease evolution and clinical heterogeneity is expanded, the arsenal of potential drugs that may ... therapy (approved drug or newer agents still in clinical trial ) is likely to be the most beneficial. While there is no single answer ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Novel therapies for myelodysplastic syndromes.

    ... therapeutic successes have prompted a new wave of clinical trials enrolling patients with myelodysplastic syndromes ... currently in development for MDS, reviewing clinical trial data related to five classes of novel therapeutics: clofarabine, a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... while sparing normal cells. Our purpose is to summarize the clinical activity and safety of intravenous (IV) rigosertib delivered by an ... A multinational pivotal phase 3 randomized clinical trial of rigosertib versus best supportive care for patients with ...

    Research Article last updated 05/22/2014 - 10:23am.

  7. A Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

    For more details on this clinical trial, including contact information, please see this trial’s listing on ... the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored ...

    Clinical Trial last updated 04/20/2017 - 11:14am.

  8. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation and participation on a clinical trial . Bone Marrow Diseases:  ...

    Research Article last updated 02/04/2014 - 1:37pm.

  9. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia and a ... therapy, transplantation and participation on a clinical trial . Am. J. Hematol. 87:692-701, 2012. © 2012 Wiley Periodicals, Inc. ...

    Research Article last updated 07/31/2012 - 2:02pm.

  10. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation, and participation on a clinical trial . Bone Marrow Diseases:  ...

    Research Article last updated 10/11/2011 - 5:58pm.